The company also missed Wall Street estimates for first-quarter profit due to a supplier issue in its pharmaceutical Diagnostics business, which it said has since been resolved.
The company also missed Wall Street estimates for first-quarter profit due to a supplier issue in its pharmaceutical Diagnostics business, which it said has since been resolved.